
Gallus Biopharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann Pick Type B Disease
Gallus Biopharmaceuticals has signed a development and manufacturing supply agreement with Genzyme.
The firm based in St. Louis, Missouri, was established in 2010 and acquired a commercial biopharmaceutical manufacturing facility from Johnson & Johnson Centocor division in 2011. In addition to process development and clinical supply services, Gallus currently produces two commercial products that are distributed globally.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.